Menu

Image of the Day: Green Eggs 

Spotted salamander (Ambystoma maculatum) embryos are tinted green by the oxygen-producing algae (Oophila amblystomatis) that grow inside.

May 19, 2017
The Scientist Staff

Spotted salamander embryos hatching out of their egg capsules    

ROGER HANGARTER                                                                                                                                                                                         

New research demonstrates that green algae not only grow inside of a spotted salamander egg, but enter cells within its body. Thus far, this is the only example of endosymbiosis in a vertebrate. 

(See J.A. Burns et al., “Transcriptome analysis illuminates the nature of the intracellular interaction in a vertebrate-algal symbiosis,” eLIFE, doi:10.7554/eLife.22054, 2017.)

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.